FDA's Overreach on Compounded Peptides The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157: Prohibited peptide and unapproved drug in supplements People are turning themselves into lab rats': the injectable peptides craze sweeping the US Well actually The Guardian FDA Proposes Exclusion of Semaglutide, Tirzepatide, Liraglutide from 503B Bulks List FDA posted on the topic LinkedIn